Recent LYEL News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2025 09:48:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2025 09:45:48 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2025 09:42:27 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2025 09:38:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/09/2025 08:23:34 PM
- Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments • GlobeNewswire Inc. • 06/09/2025 08:05:00 PM
- Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference • GlobeNewswire Inc. • 06/04/2025 08:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2025 08:41:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2025 08:39:32 PM
- Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025 • GlobeNewswire Inc. • 05/13/2025 08:05:00 PM
- Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025 • GlobeNewswire Inc. • 05/01/2025 01:00:08 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/21/2025 08:07:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/21/2025 08:05:50 PM
- Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma • GlobeNewswire Inc. • 04/15/2025 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/10/2025 08:55:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/01/2025 09:01:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2025 11:01:35 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/11/2025 08:52:52 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/11/2025 08:13:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2025 08:07:18 PM
- Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024 • GlobeNewswire Inc. • 03/11/2025 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2025 12:31:23 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2025 12:29:34 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2025 12:27:55 AM
- Lyell Immunopharma Announces Participation in Upcoming Investor Conferences • GlobeNewswire Inc. • 02/18/2025 09:05:00 PM
VAYK to Acquire Up to $9 million in Time-share Vacation Properties Through Non-Cash Deals • VAYK • Jun 11, 2025 9:45 AM
ECGI Holdings Invests in AI-Powered Fantasy Sports Startup Payday Fantasy • ECGI • Jun 10, 2025 8:30 AM
Avant Technologies Signs Letter of Intent for a Business Combination • AVAI • Jun 10, 2025 8:00 AM
NEXT10, Inc. Announces Acquisition of Torreon Group, Inc. • NXTN • Jun 9, 2025 8:42 AM
Maybacks Global Entertainment, LLC and Plex Sign Global Licensing and Distribution Agreement • AHRO • Jun 6, 2025 8:30 AM
Omega Laboratories Delivers Marijuana Breath Test Validation Packet to Cannabix Technologies Inc. - Completing Major Milestone under Strategic Partnership • BLOZF • Jun 5, 2025 8:54 AM